全球首创抗炎代谢调节剂HTD1801完成2型糖尿病III期临床研究 展现持续52周的综合获益与安全性优势
Oct 31, 2025 08:30 HKT |  |
|
全球首創抗炎代謝調節劑HTD1801完成2型糖尿病III期臨床研究 展現持續52周的綜合獲益與安全性優勢
Oct 31, 2025 08:30 HKT | |
|
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025 20:00 HKT |  |
|
康哲药业（867.HK;8A8.SG）长效抗IL-4Rα人源化单抗注射液MG-K10特应性皮炎适应症中国NDA已获受理
Oct 30, 2025 18:27 HKT | |
|
康哲藥業（867.HK;8A8.SG）長效抗IL-4Rα人源化單抗注射液MG-K10特應性皮炎適應症中國NDA已獲受理
Oct 30, 2025 18:27 HKT | |
|
康哲藥業（867.HK; 8A8.SG）簽訂眼科藥物諾適得(R)與倍優適(R)經銷協議
Oct 28, 2025 18:22 HKT | |
|
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R)
Oct 27, 2025 22:00 HKT | |
|
康哲药业（867.HK; 8A8.SG）签订眼科药物诺适得(R)与倍优适(R)经销协议
Oct 27, 2025 18:29 HKT | |
|
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
Oct 14, 2025 17:38 HKT |  |
|
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
Sep 28, 2025 15:00 HKT | |
|
康哲药业（867.HK；8A8.SG）创新药磷酸芦可替尼乳膏AD中国三期临床取得积极结果
Sep 28, 2025 11:33 HKT | |
|
康哲藥業（867.HK；8A8.SG）創新藥磷酸蘆可替尼乳膏AD中國三期臨床取得積極結果
Sep 28, 2025 11:33 HKT | |
|
WORK Medical enters strategic partnerships in bid to explore RWA initiatives
Sep 24, 2025 22:30 HKT | |
|
心肾代谢综合征（CKM）治疗的新范式 君圣泰的"一药多效"迎来价值重估
Sep 23, 2025 21:53 HKT | |
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
Sep 23, 2025 12:15 HKT | |
|
康哲药业就用于破伤风被动免疫和狂犬病被动免疫的两款创新生物制剂达成合作
Sep 23, 2025 11:16 HKT | |
|
康哲藥業就用於破傷風被動免疫和狂犬病被動免疫的兩款創新生物製劑達成合作
Sep 23, 2025 11:16 HKT | |
|
EASD 2025 | 君圣泰医药口头报告HTD1801治疗2型糖尿病临床3期研究成果
Sep 17, 2025 08:00 HKT | |
|
EASD 2025 | 君聖泰醫藥口頭報告HTD1801治療2型糖尿病臨床3期研究成果
Sep 17, 2025 08:00 HKT | |
|
HKTDC releases research report on biomedicine, Industry development drives GBA global tech leadership
Sep 15, 2025 15:19 HKT |  |
|